相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem et al.
CLINICAL CANCER RESEARCH (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
Emanuele Valtorta et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Hubert Piessevaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Which drug, and when, for patients with BRAF-mutant melanoma?
Sekwon Jang et al.
LANCET ONCOLOGY (2013)
Anticancer IGF1R classes take more knocks
Malini Guha
NATURE REVIEWS DRUG DISCOVERY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
Small-molecule ATP-competitive dual IGF-IR and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution
Meizhong Jin et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
Andrew J. Weickhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
LAS: A Software Platform to Support Oncological Data Management
Elena Baralis et al.
JOURNAL OF MEDICAL SYSTEMS (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
Shazad Q. Ashraf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Michael Pollak
NATURE REVIEWS CANCER (2012)
Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations
Francesco Galimi et al.
CLINICAL CANCER RESEARCH (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
Diane Lauren Reidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
H. Piessevaux et al.
ANNALS OF ONCOLOGY (2009)
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
Mario Scartozzi et al.
BMC CANCER (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Joan M. Carboni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Andrea Bertotti et al.
SCIENCE SIGNALING (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2008)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
